ADMA Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of 23.44% compared to ADMA Biologics's net margin of 40.12%. ADMA Biologics's return on equity of 79.75% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 53.59%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.00 which suggests that it could grow by 42.98%. Given that ADMA Biologics has higher upside potential than Catalyst Pharmaceuticals, analysts believe ADMA Biologics is more attractive than Catalyst Pharmaceuticals.

ADMA Biologics has a beta of 0.571, which suggesting that the stock is 42.882% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.252%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. ADMA Biologics's net income of $26.9M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, ADMA Biologics's price-to-earnings ratio is 22.59x while Catalyst Pharmaceuticals's PE ratio is 15.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.24x versus 5.60x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Emergent BioSolutions has a net margin of 23.44% compared to ADMA Biologics's net margin of 32.52%. ADMA Biologics's return on equity of 79.75% beat Emergent BioSolutions's return on equity of -25.37%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 53.59%. On the other hand Emergent BioSolutions has an analysts' consensus of $13.50 which suggests that it could grow by 145.9%. Given that Emergent BioSolutions has higher upside potential than ADMA Biologics, analysts believe Emergent BioSolutions is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.571, which suggesting that the stock is 42.882% less volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 2.088, suggesting its more volatile than the S&P 500 by 108.753%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are smaller than Emergent BioSolutions quarterly revenues of $209.1M. ADMA Biologics's net income of $26.9M is lower than Emergent BioSolutions's net income of $68M. Notably, ADMA Biologics's price-to-earnings ratio is 22.59x while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.24x versus 0.32x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of 23.44% compared to ADMA Biologics's net margin of -598.74%. ADMA Biologics's return on equity of 79.75% beat Ocular Therapeutix's return on equity of -56.05%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 53.59%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 144.07%. Given that Ocular Therapeutix has higher upside potential than ADMA Biologics, analysts believe Ocular Therapeutix is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.571, which suggesting that the stock is 42.882% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.759%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are larger than Ocular Therapeutix quarterly revenues of $10.7M. ADMA Biologics's net income of $26.9M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, ADMA Biologics's price-to-earnings ratio is 22.59x while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.24x versus 20.14x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of 23.44% compared to ADMA Biologics's net margin of 4.19%. ADMA Biologics's return on equity of 79.75% beat TG Therapeutics's return on equity of 19.78%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 53.59%. On the other hand TG Therapeutics has an analysts' consensus of $43.50 which suggests that it could grow by 29.5%. Given that ADMA Biologics has higher upside potential than TG Therapeutics, analysts believe ADMA Biologics is more attractive than TG Therapeutics.

ADMA Biologics has a beta of 0.571, which suggesting that the stock is 42.882% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.208, suggesting its more volatile than the S&P 500 by 120.838%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. ADMA Biologics's net income of $26.9M is higher than TG Therapeutics's net income of $5.1M. Notably, ADMA Biologics's price-to-earnings ratio is 22.59x while TG Therapeutics's PE ratio is 139.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.24x versus 13.98x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.